Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGIR | P43119 | 18/20 | 0.39 |
| ▸ | PTGDR | Q13258 | 7/20 | 0.39 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.38 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.38 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.38 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7023153 | 0.95 | PTGIR (0.36) | PTGIRPTGDRPTGER1PTGER4PTGER3 | |
| SCHEMBL7795340 | 0.85 | SMN1; SMN2 (0.38) | — | |
| SCHEMBL20856173 | 0.85 | SMN1; SMN2 (0.38) | — | |
| SCHEMBL7025600 | 0.83 | CHRM2 (0.38) | — | |
| SCHEMBL472178 | 0.83 | ALDH1A1 (0.38) | — | |
| SCHEMBL779563 | 0.83 | SMN1; SMN2 (0.37) | — | |
| SCHEMBL20162506 | 0.83 | ALDH1A1 (0.38) | — | |
| SCHEMBL22321965 | 0.81 | KDM4E (0.36) | — | |
| SCHEMBL382026 | 0.81 | KDM4E (0.36) | — | |
| SCHEMBL781866 | 0.80 | POLB (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1117669-B1 | ANTIVIRAL PURINE DERIVATIVES | UNIV CARDIFF (GB) | 2003-01-29 | — | — | EP | disclosed |
| US-20010031745-A1 | Antiviral purine derivatives | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2001-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031745-A1 | Antiviral purine derivatives | PNP, TYMP, MTAP | PTGIR 3314/4885PTGDR 3672/4885PTGER1 2037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.